Drug intelligence / Profile preview

cashew sublingual immunotherapy

Development stage: Phase 2
Lead developer: University of North Carolina at Chapel Hill
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Sublingual

Overview

Cashew sublingual immunotherapy (SLIT) is an investigational treatment for cashew allergy being developed by the University of North Carolina at Chapel Hill. This therapy involves the administration of a liquid glycerinated cashew extract under the tongue. [1, 2] The goal is to gradually desensitize the patient's immune system to cashew allergens, thereby reducing or eliminating the risk of severe allergic reactions upon accidental exposure. [1] It is being evaluated in the Phase 2 CASCADES clinical trial in children aged 1 to 11 years. [1]

Other names: Cashew SLIT

Beyond the preview

Go deeper on cashew sublingual immunotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cashew sublingual immunotherapy.

Explore the full profile